A Study of Sofosbuvir and Ledipasvir From Magicbuvir Plus 90/400 mg Tablets (Magic Pharma, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)

NCT03005210 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Magicbuvir Plus
DRUG: Harvoni (fist dose)
DRUG: Harvoni (second dose)

Sponsor

Genuine Research Center, Egypt

Collaborators

[object Object]